

# Yolanda Nyaboke Mageto, M.D., MPH., ATSF

Center for Advanced Heart & Lung Disease  
Annette C and Harold C. Simmons Transplant Institute  
3410 Worth Street, Suite 250  
Dallas, TX 75246

---

## Current Position(s)

**Professor, Department of Medicine** 2017-Present  
**Section Lead/Medical Director, Interstitial Lung Disease**  
**Baylor University Medical Center**  
**Dallas, Texas**

## Education:

Post-Doctoral: Master of Public Health (Epidemiology) 1996-1999  
Fellowship, Pulmonary Critical Care, University of Washington, Seattle WA 1995-1999  
Residency, Internal Medicine, University of Texas Southwestern, Dallas, TX 1991-1994  
M.D., Washington University, St. Louis, MO 1987-1991  
B.S. in Discipline (Phi Beta Kappa), Andrews University, Berrien Springs, MI 1982-1986

## Academic Appointments:

**Professor** 2017 - Present  
Department of Internal Medicine/PCCM  
Baylor University Medical Center/Texas A&M  
City, State

**Professor** 2015 - 2017  
Department of Internal Medicine/PCCM  
University of Vermont  
Burlington, Vermont

**Associate Professor** 2007 - 2015  
Department of Internal Medicine/PCCM  
University of Vermont  
Burlington, Vermont

**Associate Professor** 2006 - 2007  
Department of Internal Medicine/PCCM  
University of Texas Southwestern  
Dallas, Texas

**Assistant Professor** 1999 - 2006  
Department of Internal Medicine  
University of Texas Southwestern  
Dallas, Texas

**Instructor** 1998 - 1999  
Department of Internal Medicine/PCCM  
Washington University  
Seattle, Washington

**Assistant Professor** 1994-1995  
Department of Internal Medicine/GIM  
University of Texas Southwestern  
Dallas, Texas

## **Professional Positions and Experience**

**Section Lead Interstitial Lung Disease** 2017 – Present  
Center for Advanced Heart and Lung Disease  
Baylor University Medical Center  
Dallas, Texas

**Center Director – Pulmonary Fibrosis Foundation** 2018 – Present  
Center of Excellence  
Chicago, IL

**Director Interstitial Lung Disease Clinic** 2010 – 2017  
University of Vermont Medical Center  
Burlington, Vermont

**Director Pulmonary Ambulatory Care Clinic** 2010 – 2017  
University of Vermont Medical Center  
Burlington, Vermont

**Director Inpatient Pulmonary Unit** 2000 – 2007  
Parkland Memorial Hospital,  
University of Texas Southwestern  
Dallas, Texas,

**Director Chest Medicine Clinic** 1999 – 2007  
Parkland Memorial Hospital,  
University of Texas Southwestern

## **Certification and Licensure**

	<b>Years</b>
Diplomate Internal. Medicine, ABIM	1995
Pulmonary, ABIM	2000 – Present
Critical Care, ABIM	2005 – 2015
Texas State Medical License	Active
Vermont State Medical License	2007 – 2018
Washington State Medical License	1995 – 1999

## **Professional Development**

Interventional EBUS training Leahy Clinic Burlington Massachusetts	2011
Ultrasound Post Graduate Course (ATS)	2012
Core Business Education Program FAHC/University of Vermont, Fletcher Allen Center for Healthcare Management	2012

Advanced Business Education Program FAHC/University of Vermont, Fletcher Allen Center for Healthcare Management	2013
Promoting a better Learning Environment	2019
Medical Education: The Evolution Continues	2020
Engaging the Millennial Lerner	2020
Understanding intersectionality: brining visibility to the experiences and perspectives of women of color	2020
Addressing Bias in Medicine	2021
Learning to Lead and Follow Regardless of Your Title	2023
Identity-Safety-Leadership	2023
Equipping Medical Leaders	2023-2024

### **Professional Memberships and Activities**

Texas Medical Society	1991 – 2007
Society for Critical Care Medicine	2012 – 2017
American College of Chest Physicians	1995 – Present
Dallas County Medical Society	2000 – 2006
American College of Chest Physicians (FCCP):	2012 – Present
American Thoracic Society:	1995 – Present
Finance Committee Member	2023
Steering committee on Advancement and Learning, Member	2023
ATS Governance Implementation Task Force, Member	2023
Awards Committee, Member	2023
Board Member (Presidential Appointee)	2019 – 2023
Planning and Evaluation Committee, Chair	2020 – 2023
Planning and Evaluation Committee, Vice-Chair	2019 – 2020
Planning and Evaluation Committee, Member	2017 – 2018
Health Equality and Diversity Committee, Member	2017 – 2019
Nominating Committee	2017 – 2018
Membership Committee, Chair	2013 – 2017
Underrepresented in Medicine Training Award, Chair	2012 – Present
Minority Training Awards Committee, Vice Chair	2011 – 2012
Membership Committee, Member	2003 – 2007
Planning Committee, Member	2002 – 2003

### **Editorial Board Appointments**

#### **Guest Reviewer**

Chest	2023
Jama	2023
American Journal of Respiratory and Critical Care Medicine	2018 – Present
Baylor University Medical Center Proceedings	2017 – Present

## Committee Assignments and Administrative Services

### Institutional

Minority Physician Recruitment and Retention Committee: Baylor Scott and White Health/Baylor University Medical Center: Member	2023 – Present
Physician Leadership Competency Workgroup: Member: University of Vermont: Member	2015 – 2017
Subcommittee on Education and Strategic Recruitment Admissions Committee, U university of Vermont College of Medicine: Co-chair	2015 – 2017
Medical School Admissions Committee University of Vermont College of Medicine: Member	2013 – 2017
Q.A & I Committee University of Vermont Medical Center: Member	2010 – 2017
Clinical Operations Committee University of Vermont Medical Center: Member	2011 – 2017
Clinical Operations Subcommittee University of Vermont Medical Center, Pulmonary Division: Chair	2008 – 2017

### Non-Institutional

Tvardi Steering Committee, Tvardi Therapeutics, Inc	2023 – Present
DSMB United Therapeutics: Member, RIN-PF-301 and RIN-PF-302	2021 – Present
DSMB Allogenic Human Cells (hMSC) in Patients with Mild asthma University of Miami Stem Cell Institute: Chair	2015 – 2019
DSMB Allogeneic Human Cells (hMSC) in Patients with IPF via Intravenous Delivery (AETHER): University of Miami Stem Cell Institute: Chair, Scientific Advisory Committee	2013 – 2019
InterMune Pharmaceuticals	2003 – 2007

## Clinical / Quality Improvement Activities

<b>Bio-informaticist EPIC EMR:</b> Education of physicians, super user, developing registries, assist with development of workflows in the inpatient and outpatient settings, attending courses at EPIC headquarters: (20%-time effort) UVM Medical Center	2011 – 2017
<b>Electronic Medical Record QA improvement in clinical documentation</b> Developed and vetted a new medicine progress note to help improve clinical documentation and communication between services and medicine teams. Documenting only what is necessary and using problem-based charting.	2014 – 2016

**Electronic Medical Record development of COPD smart form and Registry** 2015 – 2016

Developed COPD smart form to generate an action plan for the patient and provider. Form also designed to provide action plans for triage nurses in the event of an exacerbation to provide more efficient care.

**Chronic Lung Disease Pathway:** 2014 – 2016

Developed as a member of the Chronic Lung Disease Pathway clinical protocol and standard of care Material used locally to evaluate and effect change in management. at the University of Vermont.

Contribution: Assisted with development of roadmap and components necessary for the pathway to be used successfully. Responsible for the development of E learn power point slides for primary care providers on asthma, COPD and the use of Spirometry, development of COPD smart form to be used to develop action plan for patients and plainly state goals of self-care. Developed templates for sub- specialty clinic providers to use when referring patients back to primary care providers to give them guidance in further management of these patients.

**Development of Sepsis Modified Early Warning System** 2015 – 2016

Began the process of developing and Early warning system to identify patients at risk for decompensation on the medicine floor and intervening or transferring before need for RRT. Worked with EPIC and clinical/critical care committees/nursing leadership to define to product, identify and establish buy in from staff and faculty. Modeled after the pediatric warning system.

**Educational Activities**

**Lecturer and Course Development** 2003 – 2010

Contributing Faculty PILOT Steering Committee (Pulmonary Fibrosis identification: Lessons for Optimizing Treatment) France Foundation

COPD and Lung Cancer Syllabus second year medical students 2008 – 2015  
University of Vermont

Human Biology 2<sup>nd</sup> year Medical Students 1996 – 1998.  
University of Washington.

Cardiovascular, Respiratory and Renal Course 2<sup>nd</sup> year medical students 2008 – 2017  
University of Vermont

Instructor Respiratory UTSW PA school pathophysiology course 2017 – 2019

Update in Interstitial Lung Disease Conference: 2018  
Developed, Moderated day long ILD course for Medical Professionals and Patients

**Training Program Committees:**

Fellowship Competency Committee: 2017 – Present  
Baylor Scott and White Health/Baylor University Medical Center: Member

Fellowship Program Evaluation Committee: 2014 – 2017  
University of Vermont: Pulmonary Division Representative

**Small Group Sessions**

Human Biology Tutor and Group Instructor (2<sup>nd</sup> yr. Med students) 1996 – 1998  
University of Washington

Respiratory Small Group Instructor (2<sup>nd</sup> yr., Med students) 2007 – 2016  
University of Vermont

Board Review (Pulmonary fellows) 2018 – Present  
Baylor University Medical Center Dallas

**Formal Teaching (Lectures) of Residents, Clinical and Research Fellows (post-docs)**

Rheumatologic Manifestations of Lung Disease University of Washington 1997  
Division of Pulmonary and Critical Care Medicine

Clinical Utility of BAL in Interstitial Lung Disease University of Washington 1999  
Division of Pulmonary and Critical Care Medicine

Novel Therapies in the Treatment of IPF University of Texas Southwestern 1999  
Division of Pulmonary and Critical Care Medicine

Evaluation of Dyspnea University of Texas Southwestern 2000  
Pulmonary Fellows

Evaluation of Clinical Trials University of Texas Southwestern 2001  
Pulmonary Fellows

Obstructive Lung Disease University of Texas Southwestern 2002  
Pulmonary Fellows

Sarcoidosis: University of Texas Southwestern 2005  
Division of Allergy and Immunology

Endocrine Emergencies FAHC/University of Vermont 2007  
Pulmonary Fellows, Residents and Medical Students

Idiopathic interstitial pneumonias FAHC/ University of Vermont 2007  
Pulmonary Fellows

Sarcoidosis Medicine: FAHC/ University of Vermont 2007  
Medicine Residents

Asthma in Pregnancy: FAHC/ University of Vermont: Pulmonary Fellows	2010
Sarcoidosis: FAHC/ University of Vermont: Pulmonary Fellows	2013
Diffuse Parenchymal Lung Diseases FAHC/ University of Vermont: Medicine Residents	2014
Diffuse Parenchymal Lung disease: FAHC/ University of Vermont: Medicine Residents	2016
Interstitial Lung Disease part I and II FAHC/ University of Vermont Pulmonary Fellows	2017
Interstitial Lung Disease part I and II Pulmonary Fellows Baylor University Medical Center	2018
Pulmonary Complications of Connective Tissue Disease Internal Medicine House staff Conference	2019
Hypersensitivity Pneumonitis Residents, and Medical Students Internal Medicine House staff Conference	2020
Cardiac Sarcoidosis: Baylor Heart and Vascular Hospital Faculty and Fellows	2020
Sarcoidosis update: Baylor University Medical Center Faculty and Fellows	2021
Sarcoidosis: Baylor Heart and Vascular Hospital AHF Lecture Series	2022
Interstitial Lung Disease update Internal Medicine House staff Conference 1 hour lecture	2022

**Clinical Supervisory and Training Responsibilities:**

Pulmonary outpatient clinic One half day a week supervised 1 <sup>st</sup> -3 <sup>rd</sup> yr. fellows Preceptor UTSW	1999 – 2007
Pulmonary ambulatory care clinic One half session a week Preceptor FAHC	2007 – 2016
Fellowship Board Review      Weekly	2017 – Present

ILD Clerkship preceptor      4 /year      2017 – Present

### **Honors and Awards**

Phi Kappa Phi      1986

Clinical Trials Investigator of the year - University of Texas Southwestern      2004

### **Grants and Contract Awards**

Foundation Grant: Three Lakes Foundation – \$452,000.00 2-year award Progressive Fibrosing-Interstitial Lung Disease Supplemental Care Program 2-year grant program to develop and pilot a Best Practices Supplemental Care Program for patients with progressive fibrosing ILD.  
Years:2019-2022

### **Research:**

#### **Clinical Trials: Active**

PI      2017 – Present  
Prospective Outcomes Registry of Subjects With Non IPF Pulmonary Fibrosis

PI      2022 – Present  
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis

PI      2022 – Present  
A Double-Blind, Randomized, Placebo Controlled, Two Period Cross-Over Study to Evaluate the Efficacy and Safety of Orvepitant in Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis

PI      2022 – Present  
Phase 3-A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of oral BI-1015550 over 52 weeks in patients with IPF/ Progressive Fibrosing Interstitial Lung Disease (PF-ILD); w w/o SoC

PI      2023 – Present  
A Randomized Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients with Idiopathic Pulmonary Fibrosis (IPF)

PI      2023 – Present  
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of DWN12088 in Patients With Idiopathic Pulmonary Fibrosis



PI A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over at Least 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)	2023 – Present
PI REVERT-IPF: A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis	2023 – Present
PI MOONSCAPE: A Two-Cohort, Phase II, Multicenter, Randomized, Double-blind, Parallel group, Placebo controlled study Evaluating the Efficacy and Safety of Vixarelamab compared with placebo in patients with Idiopathic Pulmonary Fibrosis and in patients with Systemic Sclerosis-associated interstitial lung disease	2023 – Present
PI ALOFT - A randomized, double-blind, placebo-controlled, phase II study to investigate the efficacy and safety of MBS 2320 in patients with idiopathic pulmonary fibrosis	2023 – Present
PI BEACON IPF, a phase of 2b clinical trial of Bexotegrast in IPF	2023 – Present

### **Completed Trials/Projects:**

PI A Randomized Double –Blind, Placebo-Controlled, International Phase III study of the Safety and Efficacy of 200ucg Subcutaneous Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis. A study to determine if Interferon Gamma-1b has an effect on mortality in early to moderate IPF as suggested but not proven in the initial trial.	2000 – 2002
PI A Phase I Study of the Safety, Pharmacokinetics, a Biologic Activity of Escalating Doses of FG-3019 in Subjects with Idiopathic Pulmonary Fibrosis	2003 – 2004
Sub PI Multicenter, Randomized, Placebo-Controlled, Double-Blind, Three-Arm Study of Evaluate the Safety and Efficacy of Tifacogin (Recombinant Tissue Factor Pathway inhibitor) Administration in Subjects with Severe Community-Acquired Pneumonia	2004 – 2006
Sub –PI Sub Investigator-Characterization of Familial Idiopathic Pulmonary Fibrosis. A study to ascertain specific identifying features of Familial IPF	2004 – 2007

Sub PI	2004 – 2007
Sub Investigator: Molecular Basis of Hereditary Cardiopulmonary Disorders: A study to identify and explore the possibility of a genetic component to hereditary pulmonary disorders specifically Idiopathic Pulmonary Fibrosis	
PI	2004 – 2007
An Open-Label Study of the safety of Subcutaneous Recombinant Interferon gamma-1b in Patients with Idiopathic Pulmonary Fibrosis. Sponsor InterMune Pharmaceuticals Inc. A continuation study of the initial large gamma Interferon trial monitoring efficacy and safety	
PI	2004 – 2007
Biomarker Discovery and the search for a diagnostic test for idiopathic pulmonary fibrosis. Sponsor InterMune Pharmaceuticals Inc. This study is an attempt to identify the presence of biomarkers in IPF that would allow one to develop a blood test that would easily identify those with the disease and those at risk	
PI	2004 – 2006
A double blind, Parallel, Placebo-Controlled, Randomized Study of the efficacy and Safety of Etanercept in Patients with Idiopathic Pulmonary Fibrosis. Sponsor: Wyeth Pharmaceuticals. Study examining the effects of Etanercept a TNF-alpha inhibitor on pulmonary fibrosis acting via its immune-modulating and anti-fibrotic effects on inhibiting TGF-beta levels in the lung	
PI	2005 – 2007
Phase III Clinical Trial of Pirfenidone in the treatment in Idiopathic Pulmonary fibrosis. Sponsor: InterMune. An international study to evaluate the efficacy and safety of a new anti-fibrotic agent in the treatment of Idiopathic Pulmonary Fibrosis	
PI	2008 – 2010
A Phase 2, Sequential, Ascending Dose Study to characterize the Safety, Tolerability, Pharmacokinetic and Biological activity of cc-930 in idiopathic pulmonary fibrosis (IPF). Sponsor: Celgene	
PI	2008 – 2011
A Phase One, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients with Idiopathic Pulmonary Fibrosis (IPF). Sponsor: Immune Works	
PI	2009 – 2012
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects with Idiopathic pulmonary fibrosis	
Sub-PI	2009 – 2015
A Randomized, Double –Blind, Placebo-controlled, phase 3 study of the efficacy and safety of Pirfenidone in patients with Idiopathic Pulmonary Fibrosis	

Local PI (sub investigator) Immune Recognition of mycobacterial antigens in Sarcoidosis Patients	2009 – 2011
PI 52-week, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150mg twice daily, on annual Forced Vital Capacity decline, in patients with Idiopathic Pulmonary Fibrosis	2012 – 2015
PI A randomized, Double blind, Placebo-Controlled, Phase 2 study of the Safety and Efficacy of BMS-986020 in subjects with Idiopathic Pulmonary Fibrosis	2012 – 2016
PI A phase 2a, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability and Efficacy of FG-3019 in Subjects with Idiopathic Pulmonary Fibrosis	2012 – 2017
PI A phase 2, Randomized, Double-blind Placebo controlled Study to Evaluate the Safety, Tolerability and Efficacy of FG-3019 in Subjects with Idiopathic Pulmonary Fibrosis	2013 – 2017
PI A phase II, Randomized, Double-Blind Placebo-Controlled study to assess the efficacy and safety of Lebrikuzimab in Patients with Idiopathic Pulmonary Fibrosis	2014 – 2015
PI A Treatment Protocol to Allow Patients in The U.S. with Idiopathic Pulmonary Fibrosis Access to Pirfenidone	2014 – 2015
PI Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) (PF-ILD): To investigate the efficacy and safety of Nintedanib over 52 weeks in patients with progressive Fibrosing Interstitial Lung Disease.	2016 – 2020
Sub- PI A Phase II, randomized, double-blind, placebo-controlled, parallel-group, Multicenter trial to evaluate the efficacy and safety of abituzumab in subjects with systemic sclerosis- associated interstitial lung disease (SSc-ILD) EMR 200017-014	2017 – 2018
Sub- PI A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma. (ANDHI).	2017 – 2021
<u>PI (Investigator Initiated)</u> Phase IV, Single-Center, Open-Label Study Evaluating the Effects of an Anti-IL5 Receptor Alpha (Benralizumab) Monoclonal Antibody in the treatment of Severe Asthma in Patients with Allergic Bronchopulmonary Aspergillosis (closed)	2019 – 2022

PI A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)	2017 – 2021
PI A Phase 2, 24-Week Randomized, Double-blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects with IPF, Followed by a 28-Week Treatment Extension	2017 – 2021
PI A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to assess the Safety and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) in subjects at risk of Pulmonary Hypertension associated with Pulmonary fibrosis on long term Oxygen therapy; (Bellepherone)	2021 – 2023
PI (Investigator Initiated (Funding Three Lakes Foundation) Progressive Fibrosing-Interstitial Lung Disease Supplemental Care Program	2021 – 2022
PI A Phase 3, Randomized, Double-Blind Placebo Controlled Efficacy and Safety study of Pamrevlumab in subjects with Idiopathic Pulmonary Fibrosis (IPF)( Fibrogen)	2020 – 2023

## Publications

### Peer reviewed publications in print or other media

1. Mageto YN, Raghu G. Genetic predisposition of idiopathic pulmonary fibrosis. Curr Opin Pulm Med. 1997 Sep;3(5):336-40. Review. PubMed PMID: 9331534.
2. Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med. 1999 Apr;159(4 Pt 1):1061-9. doi: 10.1164/ajrccm.159.4.9805017. PMID: 10194146.
3. Raghu G, Mageto YN, Lockhart D, Schmidt RA, Wood DE, Godwin JD. The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: A prospective study. Chest. 1999 Nov;116(5):1168-74. doi: 10.1378/chest.116.5.1168. PMID: 10559072.
4. Ganesh Raghu, M.D., Kevin K. Brown, M.D., Williamson Z. Bradford, M.D., Ph.D., Karen Starko, M.D., Paul W. Noble, M.D., David A. Schwartz, M.D., and Talmadge E. King, Jr., M.D. for the Idiopathic Pulmonary Fibrosis Study Group\*\* . A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2004 Jan 8; 350(2):125-33. \*\* (**Member Idiopathic Pulmonary Fibrosis Group**)
5. Brown ES, Stuard G, Liggin JD, Hukovic N, Frol A, Dhanani N, Khan DA, Jeffress J, Larkin GL, McEwen BS, Rosenblatt R, Mageto Y, Hanczyc M, Cullum CM. Effect of phenytoin on mood and declarative memory during prescription corticosteroid therapy. Biol Psychiatry. 2005 Mar 1;57(5):543-8. doi: 10.1016/j.biopsych.2004.11.021. PMID: 15737670.

6. King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, du Bois RM; **INSPIRE Study Group**. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. *Lancet*. 2009 Jul 18;374(9685):222-8. doi: 10.1016/S0140-6736(09)60551-1. Epub 2009 Jun 29. PMID: 19570573.
7. Richmond BW, Ploetze K, Isom J, Chambers-Harris I, Braun NA, Taylor T, Abraham S, **Mageto Y**, Culver DA, Oswald-Richter KA, Drake WP. Sarcoidosis Th17 cells are ESAT-6 antigen specific but demonstrate reduced IFN- $\gamma$  expression. *J Clin Immunol*. 2013 Feb;33(2):446-55. doi: 10.1007/s10875-012-9817-6. Epub 2012 Oct 18. PMID: 23073617; PMCID: PMC3850764.
8. Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, Flaherty KR, Frankel S, Oddis CV, Denton CP, Fischer A, Kowal-Bielecka OM, LeSage D, Merkel PA, Phillips K, Pittrow D, Swigris J, Antoniou K, Baughman RP, Castellino FV, Christmann RB, Christopher-Stine L, Collard HR, Cottin V, Danoff S, Highland KB, Hummers L, Shah AA, Kim DS, Lynch DA, Miller FW, Proudman SM, Richeldi L, Ryu JH, Sandorfi N, Sarver C, Wells AU, Strand V, Matteson EL, Brown KK, Seibold JR; **CTD-ILD Special Interest Group**. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. *Thorax*. 2014 May;69(5):428-36. doi: 10.1136/thoraxjnl-2013-204202. Epub 2013 Dec 24. Erratum in: *Thorax*. 2014 Sep;69(9):834. CTD-ILD Special Interest Group [added]; multiple investigator names added. PMID: 24368713; PMCID: PMC3995282. (Collaborator)
9. Saketkoo LA, Mittoo S, Frankel S, LeSage D, Sarver C, Phillips K, Strand V, Matteson EL; OMERACT Connective Tissue Disease-Interstitial Lung Diseases Working Group; OMERACT **Connective Tissue Disease-Interstitial Lung Diseases Working Group**. Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases. *J Rheumatol*. 2014 Apr;41(4):792-8. doi: 10.3899/jrheum.131251. Epub 2014 Feb 1. PMID: 24488412; PMCID: PMC4369780.
10. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; **INPULSIS Trial Investigators**. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *N Engl J Med*. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18. Erratum in: *N Engl J Med*. 2015 Aug 20;373(8):782. PMID: 24836310.  
(Collaborator)
11. Stuart BD, Choi J, Zaidi S, Xing C, Holohan B, Chen R, Choi M, Dharwadkar P, Torres F, Girod CE, Weissler J, Fitzgerald J, Kershaw C, Klesney-Tait J, **Mageto Y**, Shay JW, Ji W, Bilguvar K, Mane S, Lifton RP, Garcia CK. Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening. *Nat Genet*. 2015 May;47(5):512-7. doi: 10.1038/ng.3278. Epub 2015 Apr 13. PubMed PMID: 25848748;  
PubMed Central PMCID: PMC4414891.
12. Ganesh Raghu I, Mary Beth Scholand, João de Andrade, Lisa Lancaster, **Yolanda Mageto**, Jonathan Goldin, Kevin K Brown, Kevin R Flaherty, Mark Wencel, Jack Wanger, Thomas Neff, Frank Valone, John Stauffer, Seth Porter; FG-3019 Anti-CTGF Monoclonal Antibody - Results of an Open Label Clinical Trial in IPF. *ERJ*, DOI: 10.1183/13993003.01030-2015

13. Glassberg MK, Minkiewicz J, Toonkel RL, Simonet ES, Rubio GA, DiFede D, Shafazand S, Khan A, Pujol MV, LaRussa VF, Lancaster LH, Rosen GD, Fishman J, **Mageto YN**, Mendizabal A, Hare JM. Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial. *Chest*. 2017 May;151(5):971-981. doi: 10.1016/j.chest.2016.10.061. Epub 2016 Nov 24. PMID: 27890713; PMCID: PMC6026255.
14. Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; **INBUILD Trial Investigators**. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. *N Engl J Med*. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29. PMID: 31566307.
15. Todd JL, Neely ML, Overton R, Durham K, Gulati M, Huang H, Roman J, Newby LK, Flaherty KR, Vinisko R, Liu Y, Roy J, Schmid R, Strobel B, Hesslinger C, Leonard TB, Noth I, Belperio JA, Palmer SM; **IPF-PRO Registry investigators**. Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry. *Respir Res*. 2019 Oct 22;20(1):227. doi: 10.1186/s12931-019-1190-z. PMID: 31640794; PMCID: PMC6805665.
16. Snyder L, Neely ML, Hellkamp AS, O'Brien E, de Andrade J, Conoscenti CS, Leonard T, Bender S, Gulati M, Culver DA, Kaner RJ, Palmer S, Kim HJ; **IPF-PRO™ Registry investigators**. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. *Respir Res*. 2019 May 30;20(1):105. doi: 10.1186/s12931-019-1043-9. PMID: 31142314; PMCID: PMC6542049.
17. Todd JL, Vinisko R, Liu Y, Neely ML, Overton R, Flaherty KR, Noth I, Newby LK, Lasky JA, Olman MA, Hesslinger C, Leonard TB, Palmer SM, Belperio JA; **IPF-PRO Registry investigators**. Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort. *BMC Pulm Med*. 2020 Mar 14;20(1):64. doi: 10.1186/s12890-020-1103-4. PMID: 32171287; PMCID: PMC7071646.
18. Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M; **INBUILD trial investigators**. Nintedanib in patients with progressive fibrosing interstitial lung diseases- subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. *Lancet Respir Med*. 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5. PMID: 32145830.
19. O'Brien EC, Hellkamp AS, Neely ML, Swaminathan A, Bender S, Snyder LD, Culver DA, Conoscenti CS, Todd JL, Palmer SM, Leonard TB; **IPF-PRO Registry investigators**. Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry. *Chest*. 2020 May;157(5):1188-1198. doi: 10.1016/j.chest.2019.11.042. Epub 2020 Jan 15. PMID: 31954102.
20. Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M, Bargagli E, Chung JH, Collins BF, Bendstrup E, Chami HA, Chua AT, Corte TJ, Dalphin JC, Danoff SK, Diaz- Mendoza J, Duggal A, Egashira R, Ewing T, Gulati M, Inoue Y, Jenkins AR, Johannson KA, Johkoh T, Tamae-Kakazu M, Kitaichi M, Knight SL, Koschel D, Lederer DJ, **Mageto Y**, Maier LA, Matiz C, Morell F, Nicholson AG, Patolia S, Pereira CA, Renzoni EA, Salisbury ML, Selman M, Walsh SLF, Wuyts WA, Wilson KC. Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med* 2020 Aug 1;202(3):e36-e69. doi: 10.1164/rccm.202005-2032ST. Erratum in: *Am J Respir Crit Care Med*. 2021 Jan 1;203(1):150-151. PMID: 32706311; PMCID: PMC7397797.

21. Graney BA, He C, Marll M, Matson S, Bianchi P, Cosgrove GP, Lee JS; **PFF CCN Delphi Collaborators**. Essential Components of an Interstitial Lung Disease Clinic: Results From a Delphi Survey and Patient Focus Group Analysis. *Chest*. 2021 Apr;159(4):1517-1530. doi: 10.1016/j.chest.2020.09.256. Epub 2020 Oct 5. PMID: 33031832; PMCID: PMC7534733.
22. Salisbury ML, Conoscenti CS, Culver DA, Yow E, Neely ML, Bender S, Hartmann N, Palmer SM, Leonard TB; **IPF-PRO Registry principal investigators** as follows. Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry. *Ann Am Thorac Soc*. 2020 Nov;17(11):1413-1423. doi: 10.1513/AnnalsATS.201912-880OC. PMID: 32574517; PMCID: PMC7640723.
23. Kim HJ, Snyder LD, Adegunsoye A, Neely ML, Bender S, White ES, Conoscenti CS, Streck ME; **IPF-PRO Registry Investigators**. Hospitalizations in patients with idiopathic pulmonary fibrosis. *Respir Res*. 2021 Sep 30;22(1):257. doi: 10.1186/s12931-021-01851-4. PMID: 34592998; PMCID: PMC8481759.
24. O'Brien EC, Hellkamp AS, Neely ML, Swaminathan A, Bender S, Snyder LD, Culver DA, Conoscenti CS, Todd JL, Palmer SM, Leonard TB; **IPF-PRO Registry investigators**. Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry. *Chest*. 2020 May;157(5):1188-1198. doi: 10.1016/j.chest.2019.11.042. Epub 2020 Jan 15. PMID: 31954102.
25. Todd JL, Vinisko R, Liu Y, Neely ML, Overton R, Flaherty KR, Noth I, Newby LK, Lasky JA, Olman MA, Hesslinger C, Leonard TB, Palmer SM, Belperio JA; **IPF-PRO Registry investigators**. Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort. *BMC Pulm Med*. 2020 Mar 14;20(1):64. doi: 10.1186/s12890-020-1103-4. PMID: 32171287; PMCID: PMC7071646.
26. Todd JL, Neely ML, Overton R, Durham K, Gulati M, Huang H, Roman J, Newby LK, Flaherty KR, Vinisko R, Liu Y, Roy J, Schmid R, Strobel B, Hesslinger C, Leonard TB, Noth I, Belperio JA, Palmer SM; **IPF-PRO Registry investigators**. Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry. *Respir Res*. 2019 Oct 22;20(1):227. doi: 10.1186/s12931-019-1190-z. PMID: 31640794; PMCID: PMC6805665.
27. Snyder L, Neely ML, Hellkamp AS, O'Brien E, de Andrade J, Conoscenti CS, Leonard T, Bender S, Gulati M, Culver DA, Kaner RJ, Palmer S, Kim HJ; **IPF-PRO™ Registry investigators**. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. *Respir Res*. 2019 May 30;20(1):105. doi: 10.1186/s12931-019-1043-9. PMID: 31142314; PMCID: PMC6542049.
28. Gersten RA, Seth B, Arellano L, Shore J, O'Hare L, Patel N, Safdar Z, Krishna R, **Mageto Y**, Cochran D, Lindell K, Danoff SK; Pulmonary Fibrosis Foundation. Provider Perspectives on and Access to Palliative Care for Patients With Interstitial Lung Disease. *Chest*. 2022 Mar 17:S0012-3692(22)00442-1. doi: 10.1016/j.chest.2022.03.009. Epub ahead of print. PMID: 35305969.
29. Swaminathan AC, Hellkamp AS, Neely ML, Bender S, Paoletti L, White ES, Palmer SM, Whelan TPM, Dilling DF; Idiopathic Pulmonary Fibrosis Prospective Outcomes **Registry Investigators**. *Ann Am Thorac Soc*. 2022 Jun;19(6):981-990. doi: 10.1513/AnnalsATS.202105-589OC. PMID: 35073248

30. Gersten RA, Seth B, Arellano L, Shore J, O'Hare L, Patel N, Safdar Z, Krishna R, **Mageto Y**, Cochran D, Lindell K, Danoff SK; Pulmonary Fibrosis Foundation. Chest. 2022 Aug;162(2):375-384. doi: 10.1016/j.chest.2022.03.009. Epub 2022 Mar 17. PMID: 35305969
31. De Andrade JA, Kulkarni T, Neely ML, et al. Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the **IPF- PRO Registry**. *Respir Res*. 2022;23(1):3. Published 2022 Jan 7. doi:10.1186/s12931-021-01921
32. Raghu G, Ghazipura M, Fleming TR, Aronson KI, Behr J, Brown KK, Flaherty KR, Kazerooni EA, Maher TM, Richeldi L, Lasky JA, Swigris JJ, Busch R, Garrard L, Ahn DH, Li J, Puthawala K, Rodal G, Seymour S, Weir N, Danoff SK, Ettinger N, Goldin J, Glassberg MK, Kawano-Dourado L, Khalil N, Lancaster L, Lynch DA, **Mageto Y**, Noth I, Shore JE, Wijsenbeek M, Brown R, Grogan D, Ivey D, Golinska P, Karimi-Shah BA, Martinez FJ. Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. *Am J Respir Crit Care Med*. 2024 Jan 4. doi: 10.1164/rccm.202312-2213SO. Epub ahead of print. PMID: 38174955.

### **Non-peer reviewed scientific or medical publication materials in print or other media**

Raghu G., **Mageto Y**. Genetic Predisposition of Interstitial Lung Disease. In: Interstitial Lung Disease, 3rd edition., Eds., Schwartz MI and King T. Jr. St. Hamilton Ontario; Mosby-Yearbook 1998 p.119- 132

**Mageto Y.**: E-Learn series for Asthma and COPD for primary care pulmonary pathway. (Institutional Only)

### **Invited Editorials:**

1. Morisset J, **Mageto Y**, Raghu G. Mortality in Interstitial Lung Disease: Do Race and Skin Colour Matter? *Eur Respir J*. 2018 Jun 14;51(6). pii: 1800892. doi: 10.1183/13993003.00892-2018.
2. **Mageto Y**, The Increasing Use of Social Media for Medical Information: Should Healthcare Providers be Concerned? *Ann Am Thorac Soc*. 2019 May;16 (5):544-546. doi: 10.1513/AnnalsATS.201902-125ED.
3. **Mageto YN**. Health Care Disparities in Pulmonary Fibrosis-Time to Move the Needle Forward. *JAMA Netw Open*. 2023;6(3):e232442. Published 2023 Mar 1. doi:10.1001/jamanetworkopen.2023.2442



### **Clinical Guidelines and Reports**

1. Raghu G, Document S, Remy-Jardin M, Mageto Y, et al. **Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline** [published online ahead of print, 2020 Jul 24]. *Am J Respir Crit Care Med.* 2020;10.1164/rccm.202005-2032ST. doi:10.1164/rccm.202005-2032ST
2. Thakur N, Lovinsky-Desir S, Appell D, Bime C, Castro L, Celedón JC, Ferreira J, George M, Mageto Y, Mainous Iii AG, Pakhale S, Riekert KA, Roman J, Ruvalcaba E, Sharma S, Shete P, Wisnivesky JP, Holguin F. **Enhancing Recruitment and Retention of Minority Populations for Clinical Research in Pulmonary, Critical Care, and Sleep Medicine: An Official American Thoracic Society Research Statement.** *Am J Respir Crit Care Med.* 2021 Aug 1;204(3):e26-e50. doi: 10.1164/rccm.202105-1210ST. PMID: 34347574.
3. Bhakta NR, Bime C, Kaminsky DA, et al. **Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement.** *Am J Respir Crit Care Med.* 2023;207(8):978-995. doi:10.1164/rccm.202302-0310ST

### **Published Abstracts and Presentations:**

1. Ganesh Raghu, Mary Beth Scholand, **Yolanda Mageto**, Jonathan Goldin, Seth Porter, Thomas Neff, Frank Valone, Loredie Lugos, John Stauffer. Safety And Efficacy of Anti-CTGF Monoclonal Antibody FG-3019 For Treatment Of Idiopathic Pulmonary Fibrosis (IPF): Results Of Phase 2 Clinical Trial Two Years After Initiation. American Thoracic Society 2014
2. Ganesh Raghu, Mary Beth Scholand, **Yolanda Mageto**, Jonathan Goldin, Seth Porter, Thomas Neff, Frank Valone, Loredie Lugos, John Stauffer; Extended Treatment of Idiopathic Pulmonary Fibrosis with Anti-CTGF Monoclonal Antibody FG-3019: Interim Results of Phase 2 Clinical Trial. PFF Summit on IPF 12/2013
3. **Mageto Y**, Flaherty K, Brown K, Fong A, Raghu G. Safety and Tolerability of Human Monoclonal Antibody FG-3019, Anti-Connective Tissue Growth Factor, in Patients with Idiopathic Pulmonary Fibrosis. *Chest* 2004;124:773S
4. **Mageto Y**, Lockhart D., Chang. J., Schmidt., Godwin., Raghu G. Is Open Lung Biopsy/Thoracoscopic Lung Biopsy Necessary for the Diagnosis of Interstitial Lung Disease? *AARD* 1998:A277
5. **Mageto Y**, Chegini S, Schmidt R, Emond M, Raghu G. Is Differential Cellular Profile in Bronchoalveolar Lavage Useful in the diagnosis of interstitial lung disease? *AARD* 1997;133:A319
6. Tobin R, Porter A, **Mageto Y**, Pope C, Raghu G. Gastroesophageal Reflux in Idiopathic Pulmonary Fibrosis. *AARD* 1997;155:A316
7. Raghu G, **Mageto Y**, Lurton J, Emond M. Treatment of idiopathic pulmonary fibrosis (IPF) with a new antifibrotic drug - Pirfenidone (PFD). *AARD* 1997; 155:A741

**National/International Meetings**

Date

**Local/Regional Meetings (Invited)**

The Relationship Between Asthma and GERD SGNA (Southern Gastroenterologist Nursing Association) Dallas, Texas	2000
Pulmonary Fibrosis: 'A Disease that has come into its own': Internal Medicine Update UTSW	2005
Research, Evaluation and Treatment of Pulmonary Fibrosis American Lung Association CME Conference Irving, Texas	2005
Understanding, Preventing and Managing COPD Lecture Series Johns Hopkins School of Medicine (sponsor), Dallas Texas	2004
Idiopathic Interstitial Pneumonias: Making sense of alphabet soup Internal Medicine Grand Rounds, University of Texas Southwestern Dallas	2005
Collagen Vascular Associated Lung Disease: A Multidisciplinary Approach Grand rounds University of Vermont/Fletcher Allen Healthcare	2010
Diffuse Parenchymal Lung diseases: Idiopathic Pulmonary Fibrosis Grand Rounds University of Vermont/Fletcher Allen Healthcare	2014
Grand Rounds Baylor All Saints Hospital Fort Worth Texas	2019

**Report of Regional, National and International Invited Teaching and Presentations  
(Invited)**

Genetic Predisposition of IPF American Thoracic Society Meeting San Diego	1999
Diagnosis and Management of IPF in 2005 Atlanta, Georgia	2005
Making Sense of Alphabet Soup: Idiopathic Interstitial Pneumonia American Thoracic Society Meeting San Diego	2006
Idiopathic Pulmonary Fibrosis: Trends and Update in Management and Treatment. New York Health and Hospitals Cooperation	2014
Idiopathic Pulmonary Fibrosis: Update in diagnosis and management Northeast Medical Center, Vermont	2016
Idiopathic Pulmonary Fibrosis: Update in diagnosis and management IPF support group Tulsa OK	2018
Interstitial Lung Disease: What you need to know in 2018: Grand Rounds Texas Tech, Lubbock Texas	2018
Update in Internal Medicine Hendricks Medical Center Abilene: Diagnosis and Management of COPD	2020
Annual Physician CME Virtual Symposium. It takes a Village: A Practical Approach to the Recognition, Diagnosis, and Management of Interstitial Lung Disease. Hendricks Hospital	2021
Black Health Matters Spring Health Summit: Interstitial Lung Disease and Pulmonary Fibrosis an overview and Clinical Trials Update	2022
Coughing 101 for PF/ILD patients: PF Warriors Support group (Members worldwide)	2023

<b>Grand Rounds Presentations</b>	Date
Update in the Management and Diagnosis of Community Acquired Pneumonia Internal Medicine Grand Rounds, UTSW, Dallas, Texas	2004
University of Texas Southwestern It's just a little COPD: Update Geriatric Grand Rounds UTSW	2005
Update in the Management and Diagnosis of Community Acquired Pneumonia Geriatric Grand Rounds, UTSW, Dallas, Texas	2005
Interstitial Lung Disease: Alphabet Soup Fletcher Allen Healthcare/University of Vermont	2009
Connective Tissue Lung Disease Fletcher Allen Healthcare/University of Vermont	2012
It Takes a Village: A Practical Approach to the Recognition, Diagnosis, and Management of Interstitial Lung Disease Baylor All Saints Fort Worth Texas	2019
Interstitial Lung Disease what you need to know. Texas Tech Dept of Medicine Grand Rounds	2018
It Takes a Village: A Practical Approach to the Recognition, Diagnosis, and Management of Interstitial Lung Disease Hendricks Hospital	2021
COPD: Hendricks Hospital Abilene Texas	2020
Sarcoidosis the Great Masquerader University of Texas Tyler	2022
<b>Professional Community Activities</b>	
Medical Board Advisor PF warriors support group	2017 - present